Edges in Network
| Network | GSE16446_top8000 - GSE16446 - SiGN-BN NNSR |
| Network Description | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| Node | UBE2L6 |
| Upstream (Parents) |
|---|
| (<<) PSMB9 → UBE2L6 |
| (<<) APOL3 → UBE2L6 |
| (<<) PARP9 → UBE2L6 |
| (<<) IFI35 → UBE2L6 |
| Downstream (Children) |
|---|
| UBE2L6 → PSMB10 (>>) |
| UBE2L6 → IRF9 (>>) |
| UBE2L6 → SLITRK6 (>>) |
| UBE2L6 → BMPR1B (>>) |
| UBE2L6 → IGFBP2 (>>) |
| UBE2L6 → RARRES3 (>>) |
| UBE2L6 → STAT1 (>>) |
| UBE2L6 → LGALS3BP (>>) |
| UBE2L6 → PSMB9 (>>) |
| UBE2L6 → WARS (>>) |
| UBE2L6 → BATF2 (>>) |
| UBE2L6 → HLA-C (>>) |
| UBE2L6 → SMAD6 (>>) |
| UBE2L6 → LGALS9 (>>) |
| UBE2L6 → TLR3 (>>) |
| UBE2L6 → PSMB8 (>>) |
| UBE2L6 → HLA-J///HLA-H///HLA-G///HLA-B///HLA-A (>>) |
| UBE2L6 → PARP9 (>>) |
| UBE2L6 → HLA-B (>>) |
| UBE2L6 → IFI35 (>>) |
| UBE2L6 → PSME2 (>>) |
